Compounded Semaglutide vs Ozempic: Safety Concerns

Research-informed explainer — last updated 2026-04-11

Compounded semaglutide and brand-name Ozempic contain the same active molecule, but they are not the same product. Brand semaglutide — the version in Ozempic and Wegovy — was tested in large clinical trials at specific doses with a defined formulation. Compounded versions are mixed by individual pharmacies and have not gone through FDA approval for safety, potency, or sterility. That gap matters more than it sounds, and this article explains why.

This explainer draws on peer-reviewed research from three specialists listed in the Convene directory: Ildiko Lingvay, MD, Professor of Internal Medicine/Endocrinology at UT Southwestern and Parkland Health, who was among the principal investigators on the SUSTAIN-7, STEP 2, STEP 3, and SELECT cardiovascular outcomes trials — the largest body of semaglutide evidence in existence; John Buse, MD, Director of the Diabetes Center at the University of North Carolina, who co-drafted the major ADA/EASD consensus statements on GLP-1 therapy for type 2 diabetes; and Caroline Apovian, MD, Co-Director of the Center for Weight Management and Wellness at Brigham and Women's Hospital and Harvard Medical School, who co-drafted both the AHA/ACC obesity management guidelines and the Endocrine Society's clinical practice guideline on pharmacological obesity treatment.

What compounded semaglutide actually is

Compounding pharmacies are facilities authorized to mix custom medications — usually for patients who need a dose strength, formulation, or combination that isn't commercially available. During the Ozempic and Wegovy shortage that began in 2022, the FDA placed semaglutide on its drug shortage list. That designation temporarily allowed compounders to produce semaglutide-based injections without the normal FDA approval process.

The shortage designation gave many patients access to a lower-cost injectable when the brand-name product was unavailable. It also created a market with very little oversight. Compounders are regulated at the state level, standards vary, and third-party testing of these products has found problems including incorrect concentrations, impurities, and unlabeled additives. Some compounders have marketed formulations containing semaglutide "salts" — chemical variants like semaglutide acetate or semaglutide sodium — rather than the base molecule used in clinical trials. The FDA has stated that these salt forms are not the same as approved semaglutide and have not been shown to be safe or effective.

What the clinical trials actually tested

The safety and efficacy record for semaglutide comes entirely from the brand-name formulation, at specific doses, under controlled conditions.

The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity who did not have type 2 diabetes [2]. Participants received either semaglutide 2.4 mg weekly or placebo, alongside lifestyle counseling. After 68 weeks, the semaglutide group lost an average of 14.9% of body weight versus 2.4% in the placebo group. Crucially, the trial used a specific dose escalation schedule — starting at 0.25 mg weekly, increasing gradually over 16 weeks — to allow patients to adjust to the drug and minimize gastrointestinal side effects.

The STEP 2 trial, published in The Lancet in 2021, studied semaglutide 2.4 mg in 1,210 adults who had both obesity and type 2 diabetes [4]. Average weight loss was 9.6% at 68 weeks with semaglutide versus 3.4% with placebo. The same structured dose escalation protocol was used.

The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 people with established cardiovascular disease and obesity, none of whom had diabetes [3]. Over a mean follow-up of nearly 40 months, semaglutide 2.4 mg reduced the rate of heart attack, stroke, or cardiovascular death by 20% compared to placebo (hazard ratio 0.80). This is the largest cardiovascular outcomes trial in this drug class to date.

None of these trials used compounded semaglutide. The benefits, the side-effect profile, and the cardiovascular outcomes data all belong to the brand-name formulation tested at the doses and concentrations studied.

At a glance

The regulatory shift in 2024–2025

In February 2024, the FDA removed semaglutide from its official shortage list, finding that the brand-name supply had normalized. That removal changed the legal picture for compounders. Once a drug is no longer on the shortage list, the legal basis for producing compounded versions under the shortage exemption expires. The FDA issued guidance in late 2024 warning that compounding of semaglutide was no longer legally authorized under the shortage pathway.

This matters for patients currently using compounded products. A pharmacy that continues producing semaglutide after the shortage designation expires may be operating outside the legal framework that previously permitted it. Patients who transitioned to compounded versions during the shortage should ask their prescriber about next steps — either transitioning to a brand-name product or, if that's not possible, documenting why the current approach is appropriate.

Why dosing accuracy matters more than you'd expect

Semaglutide works through a dose-response relationship. The approved products follow a specific escalation from 0.25 mg to 0.5 mg to 1.0 mg for Ozempic (diabetes indication), and from 0.25 mg all the way up to 2.4 mg for Wegovy (weight management). Each step is calibrated to balance efficacy against tolerability.

If a compounded product delivers more semaglutide than labeled — even by 20% — the patient effectively gets a higher dose than expected. That raises the risk of nausea, vomiting, and the more serious but rare complication of severe gastroparesis (very delayed gastric emptying). If it delivers less, the patient may believe they are on a therapeutic dose when they are not.

Third-party testing has found both kinds of errors in marketed compounded semaglutide products. The clinical trial data that shows what doses are safe and effective — including the dose escalation protocols studied by Lingvay and colleagues in STEP 2 and SUSTAIN-7 [4][5] — cannot simply be transferred to a product with uncertain potency.

What the clinical guidelines recommend

The ADA/EASD consensus framework on management of hyperglycemia in type 2 diabetes, updated in 2022 with John Buse as corresponding author, recommends GLP-1 receptor agonists — including semaglutide — for patients with established cardiovascular disease, high cardiovascular risk, or significant obesity alongside diabetes [8]. This recommendation is grounded in the cardiovascular outcomes trial data, including the SUSTAIN-6 results [1].

The Endocrine Society clinical practice guideline on pharmacological management of obesity, co-drafted by Caroline Apovian, identifies FDA-approved agents as the appropriate treatment options for chronic weight management [10]. The guideline framework assumes that the drugs used are the specific formulations that underwent clinical testing — not variants or approximations of them.

Neither guideline addresses compounded semaglutide specifically. What they reflect is the principle that evidence-based treatment means using treatments whose safety profile is actually known. The 2013 AHA/ACC obesity guideline, which Apovian also co-drafted, frames drug selection around benefit-risk ratios established through controlled trials [9]. Compounded semaglutide, by definition, lacks those trials.

Questions to ask your doctor

• Is the product I'm using brand-name or compounded? If compounded, is it still legally authorized now that the shortage designation has ended?
• If I've been using a compounded version, what's the plan to transition to a brand-name product or confirm my current approach is clinically appropriate?
• What dose am I actually getting, and how does that compare to the doses shown to be effective and safe in clinical trials?
• My insurance doesn't cover Wegovy. What options do I have — manufacturer savings programs, prior authorization, or alternative formulations?
• If I'm using semaglutide for weight management and have cardiovascular risk factors, is the SELECT trial's cardiovascular benefit relevant to my situation?

The bottom line

The clinical evidence for semaglutide — including the cardiovascular outcomes data from SELECT showing a 20% reduction in serious heart events — comes from brand-name Ozempic and Wegovy, at specific doses, in large randomized trials [2][3]. Compounded semaglutide has not been tested in those trials. It may contain incorrect concentrations, impurities, or non-approved salt forms, and its legal status changed when the FDA removed semaglutide from the shortage list.

That doesn't mean everyone who used a compounded product during the shortage was harmed — many weren't. But it does mean the risk-benefit calculation is different from what the trials show. If you are currently using a compounded product or considering one, talk to an endocrinologist or obesity medicine specialist about whether the brand-name product is an option, and what the actual tradeoffs are for your specific health situation.